Company name: Elcelyx Therapeutics.
Industry: Pharmaceuticals.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Location: San Diego, California.
Solution/product: Lovidia is a dietary supplement that helps in weight loss; NewMet treats type 2 diabetes.
Money raised: $4 million of a $7 million extension round; filings show it has raised $20 million to date.
How it will be used: To fund clinical trials of Lovidia and NewMet.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Investors: Morganthaler Ventures, Kleiner Perkins Caufiled & Byers, Technology Partners.
Management team: Dr. Alain Baron, president and CEO; Martin Brown, chief business officer; Mark Fineman, vice president of R&D; Mark Wiggins, senior vice president, business development.
Market size: Market for antiobesity drugs to reach $3.1 billion by 2016; global type 2 diabetes therapeutics market will be $45.1 billion by 2020.
Competitors: Eli Lilly, Novo Nordisk, GSK — diabetes; Vivus, Arena Pharmaceuticals — weight loss drugs.
[Photo Credit: Freedigitalphotos.net]
